Profit taking weighs down shares of Transgenomic

LifeLab selected Transgenomic Inc.'s (Nasdaq: TBIO) ICE COLD-PCR technology as its mutation enrichment platform for cancer testing but the stock price fell as investors locked in profits.



Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.